Regulatory peptides are present in most of the tissues of the body where they are stored in and released from widespread specific endocrine cells and neurons. Regulatory peptides are believed to participate in the regulation of several body functions including digestion, respiration, kidney functions, mental functions, cardiovascular functions and response to injury. The kidneys play an important role in the metabolism and excretion of several regulatory peptides (1) (2) (3) , and many regulatory peptides regulate or modulate kidney functions, either directly by acting on the glomerulus and tubular systems (4, 5) or indirectly by acting on the cardiovascular system, renin-angiotensin-aldosterone system, the antidiuretic hormone or the adrenergic or cholinergic nervous systems. Kidney disfunction, therefore, results in derangement (usually elevations) of peptide concentrations in plasma. Furthermore, renal failure and hemodialysis are frequently accompanied by symptoms from several organ systems, some of which may be partly due to elevated concentrations of regulatory peptides in the circulation. Of particular interest in this context are the cardiovascular, renal, gastrointestinal and inflammatory effects of regulatory peptides known to be present in elevated concentrations in renal failure.
Chronic renal failure is frequently associated with hypertension, and hypotensive episodes may develop during hemodialysis. Vasoactive regulatory peptides are likely to playa role in the pathogenesis of these cardiovascular symptoms. Several regulatory peptides have powerful effects on the motility and secretory mechanisms of the gastrointestinal tract. Elevated plasma concentrations of these peptides may contribute to the anorexia, nausea and diarrhea associated with renal failure. Itching, a distressing symptom of renal failure, is frequently associated with secondary hyperparathyroidism, which, however, cannot be the sole pathogenetic mechanism of this symptom. Interestingly, several regulatory peptides which are present in elevated plasma concentrations in renal failure have been shown to participate in inflammatory reactions in the skin, and cause itching upon local injection in the skin.
The purpose of the present brief presentation is to bring together information about regulatory peptides in renal failure, with emphasis on the renal, cardiovascular and gastrointestinal systems and on symptoms which may be due to derrangement of the peptidergic transmittors. The well known important role of the renin-angiotensin-aldosterone system in this respect will only be briefly mentioned whereas emphasis will be on the more recently discovered peptides atrium natriuretic peptide (ANP), calcitonin gene-related peptide CGRP), endothelin, neuropeptide Y (NPY), vasoactive intestinal polypeptide (VIP) and the tachykinins (TK). ANP because of its established role in sodium and volume regulation under conditions of chronic fluid overload and NPY, VIP, tachykinins, CGRP and endothelin because of their unequivocal presence in perivascular nerve structures. Several of these latter regulatory peptides are believed to participate in the non-adrenergic, non-cholinergic nervous control of the cardiovascular nervous system, in control of secretory mechanisms and smooth muscle functions as well as in inflammatory reactions. Furthermore, since drugs which decrease the plasma concentrations of regulatory peptides have become available recently for use in humans, the potential benefit of these drugs in selected patients with renal failure will be discussed.
Renal metabolism of regulatory peptides
Metabolism and excretion of regulatory peptides in the kidneys accounts for a major fraction of their total metabolic clearance rate in mammals (6, 7). Inactivation of regulatory peptides in the kidney is accomplished by at least three different mechanisms; a) endocytosis by the proximal tubular cells by a process initiated by the binding of the cationic amino acids in the peptides to the negative charges of the luminal membrane. The endocytic vesicles subsequentlyfuse with Iysozymes in the tubular cells. The Iysozymes in turn hydrolyze the peptides to amino acids which partially reenter into the circulation by way of the peritubular capillary network. This process has very high capacity and is not saturable within the range of normal filtered load of peptides, b) hydrolysis by specific enzymes at the brush border and peritubular cell membranes, c) binding of the regulatory pep tides to high affinity receptors which have as their major function the removal of regulatory peptides from the circulation. In contrast to the endocytotic process, the enzymatic and receptor binding processes are saturable. However, in conditions of renal failure with reduced functioning renal parenchyma, all these processes will function suboptimally.
Regulatory peptides involved in fluid and sodium homeostasis
It is probable that a large number of sodium and fluid homeostatic regulatory peptides are released from the heart, gastrointestinal tract, liver, and possibly the brain. The role of atrium natriuretic polypeptide (ANP) in this respect is well established and has been the subject of numerous studies recently (8-10), The overwhelming interest in ANP recently may temporarily have overshadowed the role of organs other than the heart and regulatory peptides other than ANP in the peptidergic control of the sodium and fluid balance. It is for example well known that acute administration of sodium in the gastrointestinal tract results in greater natriuretic response than if the sodium was administered intravenously. It is therefore likely that there is a sodium monitor located in the gastrointestinal and/or portal tracts which triggers the release of humoral natriuretic mediators (11) (12) (13) . Furthermore, the role of vasoactive intestinal polypeptide in this respect has been clarified (14, 15) .
Role of individual peptides

Atrium Natriuretic Peptide (ANP)
Atrial natriuretic peptide represents a family of peptides of which the a, f3 and T forms have been isolated from human atrial tissues. Circulating ANP in 150 humans mainly consists of the a form (16) . The ANP family of peptides is becoming established as a new hormonal system in control of body fluid homeostasis. Changes in plasma ANP levels have been surprisingly small during major manipulations of fluid balance in normal man, thereby casting doubt on the importance of the ANP hormonal system under physiological conditions. However, during conditions of chronic fluid overload as in renal failure, heart failure or primary aldosteronism when the ANP system is already stimulated, the ANP system reacts very promptly to acutely increased fluid overload. This suggests that the ANP system is of pathophysiological importance in conditions of chronic fluid overload (17) .
Factors influencing the plasma concentration of ANP
ANP is released from the heart in response to atrial distension secondary to an increase in central blood volume and/or in response to increased right or left atrial pressures. The plasma concentration of ANP varies with age. Plasma ANP is higher in neonates than in infants and adoloscents and increases markedly from the third to the seventh decades of life (18, 19) . Pathological conditions which elevate plasma ANP are heart failure, primary aldosteronism, chronic renal failure (20) and essential hypertension (21) . Furthermore, increasing evidence indicates that measurement of ANP in plasma may be a useful indicator of fluid balance in patients with congestive heart failure and renal failure (22, 23) . Glucocorticoids as well as mineralocorticoids administered in high doses increase plasma ANP. or mild hypotension due to decrease in total peripheral vascular resistence without a concomitant rise in cardiac output. The effects of ANP on the cardiovascular system are mediated by a combination of direct and indirect effects. ANP has direct vasodilatory effects on most arteries, except the coronary arteries. Furthermore it acts indirectly by lowering plasma renin activity, plasma aldosterone, plasma vasopressin, the angiotensin-induced drinking response and by opposing the vasoconstrictor effects of angiotensin II (27) . Thus ANP may be described as a potent antagonist of several vasoconstrictors with weak vasodilatory action of its own (28) .
Renal effects
ANP induces diuresis and natriuresis by a combination of renal hemodynamic changes and inhibition of tubular transport mechanisms (8) . Its effects on the kidney may be summarized as; a) an increase in glomerular hydraulic pressure without an increase in renal blood flow mediated by dilatation of the afferent arterioles and vasoconstriction of the efferent arterioles, resulting in increased glomerular capillary hydraulic pressure, filtration fraction, and glomerular filtration rate, b) suppression of tubuloglomerular feedback, c) inhibition of sodium transport in the proximal tubules and possibly ascending limbs of the deep nephrons, d) direct stimulation of glomerular filtration, e) inhibition of the effect of angiotensin II (29) and f) by antagonizing the antidiuretic hormonemediated tubular water permeability (30, 31) .
Metabolism of ANP
The plasma half life of ANP is about 0.5 min in the rat (32, 33) , and about 4.5 min in humans (34) (35) (36) (37) . The kidney is believed to be responsible from between 14% to about 50% of the plasma clearance of ANP (5, 33). ANP is probably rapidly taken up by cells since whole blood or plasma do not result in any major degradation of ANP (32) . ANP is rapidly hydrolysed by enzymes in the kidney e.g. by endopeptidase- 24.11 (5, 38) . The concentration of immunoreactive ANP in urine is increased in patients with chronic renal failure, indicating decreased metabolic capacity of the kidneys (39) . In non-dialyzed patients with chronic renal failure a part of the immunoreactive ANP corresponds to high molecular weight (approximately 1500 Dalton) ANP (40) .
ANP and chronic renal failure
Plasma concentrations of ANP are elevated in patients with chronic renal failure, and hemodialysis significantly reduces the plasma concentrations of ANP in these patients (17, (19) (20) (21) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) . Several factors may contribute to the increased plasma concentrations of ANP in chronic renal failure; a) increased release of ANP in response to atrial distension due to volume overload and elevated blood pressure, b) decreased metabolism of a-ANP secondary to decrease in functioning renal parenchyma, c) the release of a prohormone of ANP with longer half life in plasma than a-ANP (51) and d) increased tissue receptor sensitivity (52) . The fall in plasma concentrations of ANP in response to dialysis (42, 49, 53, 54) is mainly due to decreased release of ANP from the atria caused by the decrease in blood volume and to a less extent due to increased plasma clearance of ANP due to dialysis of the peptide.
ANP is a sensitive marker to detect the frequent complication of fluid overload in patients with chronic renal failure (42, 48, 49) . Increases in plasma concentration of ANP in chronic renal failure strongly correlate with the degree of volume overload. Thus almost normal plasma concentrations are found in chronic renal failure without fluid retention (42) . If high ANP concentrations persist after intensive ultrafiltration in patients undergoing hemodialysis, it indicates congestive heart failure in need of specific therapy (55) . Furthermore, there is a positive correlation between blood pressure and plasma concentration of ANP in renal failure (20, 44, 56) . Data on the correlation of plasma ANP to the concentration of serum creatinine have been controversial (44) (45) (46) , possibly due to the presence of confounding variables such as volume overload, age and blood pressure.
AN~and the nephrotic syndrome
Baseline plasma concentrations of ANP are depressed in adult patients with the nephrotic syndrome but increase appropriately upon induced hypervolemia (57) . However, the renal tubules exhibit insensitivity to transient hypervolemia (57, 58) and insensitivity to exogenous ANP (59) in the nephrotic syndrome. It is therefore likely that the developmentof the nephrotic syndrome is associated with tubular insensitivity to ANP and to other factors/hormones that normally regulate tubular sodium transport (57) . However, in children with the nephrotic syndrome the plasma concentrations of ANP appear to be normal and the diuresis, natriuresis and glomerular filtration rate correlate With the plasma concentration of ANP (60) . The present evidence thus indicates that ANP may play an important pathophysiological role in the nephrotic syndrome. It is possible that a-ANP may be of therapeutic use in this condition since infusion of a-ANP results in increased urine volume and sodium excretion in patients with the nephrotic syndrome (61) .
Renal transplantation
In renal transplant recipients, neither the renal denervation nor the use of immunosuppressive therapy abolishes the influence of age, systolic blood pressure and renal function of the plasma levels of ANP (62) .
Experimental models of renal failure and potential therapeutic effect of ANP in patients with renal failure or after renal transplantation
In different animal models of renal failure, exogenously administered ANP increases glomerular filtration rate, diuresis and natriuresis (52, 59, (63) (64) (65) (66) (67) . Furthermore, infusion of a-ANP may be beneficial to prevent tissue damage in the kidneys and ANP may have beneficial effects on the renal function in the early phases following transplantation (64) .
The evidence summarized above indicates that infusion of ANP has potential therapeutic use in renal diseases in the human. This has been confirmed in studies where infusion of a-ANP or ANP produced a dose-dependant increase in diuresis and natriuresis in patients with moderate renal impairment, chronic renal failure or with the nephrotic syndrome (61, 68) .
Regulatory peptides in primary sensory neutrons
Afferent impulses are classically transmitted to the central nervous system which monitors them and 152 takes appropriate actions. The sensory nerves may, however, also play a significant "efferent" role by releasing transmittors including regulatory peptides from the C-fibres in response to activation of sensory receptors. The release is accomplished by an axonreflex mechanism or via direct release from the nerve terminals. An impulse initiated in the peripheral branch of a sensory neuron, therefore, is not only transmitted to the central nervous system where it elicits a variety of sensations, but also results in the release of transmitters from the peripheral end of the sensory nerve which causes vasodilatation and plasma protein extravasation i.e. "neurogenic inflammation" (69-72). These dual "sensory-efferent" functions of the afferent nerves may playa role in inflammatory reactions and in various other pathological states of the respiratory, genitourinary, gastrointestinal and cardiovascular systems. Furthermore, drugs which selectively affect the sensory-efferent functions are being developed and will potentially be of use for the treatment of several human diseases.
Several regulatory peptides occur in primary afferent neurons and participate in the sensory-efferent functions. The most thoroughly studied in this respect are the tachykinins (substance P (SP), neurokinin A (NKA), neurokinin B (NKB) and neuropeptide K (NPK)) and calcitonin gene-related peptide which will be discussed briefly below.
The kidneys have ample supply of afferent nerve fibers which are located in the renal pelvis and around large blood vessels (73) (74) (75) . On the basis of the content of neuropeptides, there seem to be at least four separate populations of sensory axons present; two large groups containing substance P and calcitonin gene-related peptide alone, and one small group containing both peptides and one small group containing neither (75) . Renal afferent nerves are stimulated by chemical and mechanical stimuli. Several reno-renal reflexes have been described which provide strong evidence for the involvement of renal afferent nerves not only in nociception but also in the control of the fluid balance, electrolyte balance and blood pressure (76) (77) (78) .
Calcitonin gene-related peptide (CGRP)
CGRP is a 37 amino acid residue neuropeptide generated by alternative splicing of calcitonin gene transcripts (79, 80) . It frequently coexists with tachykinins, galanin, somatostatin and acetylcholine in certain central and peripheral neurons. CGRP has been isolated in four different forms; a and f3 forms from human tissues and a and f3 forms from rat tissues. Studies on the structure-activity relationship of CGRP have demonstrated that, apart from minor differences, the four CGRP sequences behave similarly. CGRP is mainly present in dense nerve plexuses around vessels and in the conducting tissues of the heart. Highly specific CGRP receptors have been identified in the intima and media of vessels, particularly in arteries and in the heart. Circulating CGRP is mainly derived from perivascular and cardiac nerves and to some extent from the thyroid (81, 82) .
Cardiovascular effects
CGRP is one of the most potent vasodilators known (83) . In humans vasodilation caused by CGRP is long-lasting, with a half life of approximately 18 min, whereas e.g. the half life of the vasodilation caused by tachykinins such as substance P is approximately 15 sec (84) . The vasodilation is evidenced by the facial flushing which is marked upon intravenous infusion of CGRP to man (85) . The cardiovascular effects of CGRP cannot be blocked by muscarinic, adrenoceptor or histamine blockers, and are not either affected by prostaglandin synthesis inhibitors. Even though CGRP in itself evokes little or no protein extravasation, it increases the plasma extravasation induced by substance P (86) . It is a matter of debate whether the vasodilating action of CGRP depends on an endothelium-derived relaxant factor released from an intact endothelium. The vasodilation, however, seems to be endothelium dependant in major vessels. CGRP has potent chronotropic and inotropic effects on the heart (87), and CGRP is currently the only peptide transmittor with an established role in cardioacceleration via non-adrenergic non-cholinergic nerves to the cardiac pacemarker. The plasma concentration of CGRP is decreased in spontaneously hypertensive rats (88) and the CGRP response to intravenous calcium is related to blood pressures in humans (89) . Thus upon calcium infusion there was a decrease in plasma CGRP among those with higher blood pressures, whereas plasma CGRP increased among those with lower blood pressure (89) . It is, therefore, probable that CGRP may playa role in the pathogenesis of hypertension.
Renal effects
There seem to be species differences in the renal effects of CGRP. Infusions of CGRP to dogs dilate the renal arteries and increase renal blood flow and creatinine clearance without influencing urinary sodium excretion or plasma renin activity (90) . However, in the rat, while the hemodynamic effects are similar to the dog, the sodium excretion is unchanged (91) . In humans, infusion of CGRP results in an increase in urinary volume and in the urinary calcium, sodium, potassium and chloride excretion (92) . The renal hemodynamic actions in the dog are partially inhibited by indomethacin (90) . Immunoreactive CGRP has been demonstrated both in rat renal cortical and medullary fibers, and intact CGRP in extracts of the rat renal cortex. CGRP is released from sensory nerves in the urinary tract in rats in response to capsarcin, indicating that CGRP plays a role in the sensory-efferent functions of the urinary system (93, 94) . Furthermore, CGRP stimulates the release of renin from renal juxtaglomerular cells. It is therefore probable that CGRP released from afferent nerves in the kidneys may be involved in the physiological control of renin secretion (95) .
We have recently observed that plasma concentration of CGRP increases during hemodialysis. This is in contrast to the decrease in plasma concentrations of the majority of other regulatory peptides in response to hemodialysis. Plasma concentrations of CGRP strongly correlated to systolic blood pressure before and at the end of dialysis. Furthermore, the increase in CGRP levels were not correlated to the fluid removal, toxin removal or changes in osmolality. These findings indicate that the increase in plasma concentrations of CGRP observed during dialysis may be an important cause of dialysis-induced vasodilation and fall in blood pressure (96) .
Tachykinins (substance P (SP), neurokinin A (NKA), neurokinin B (NKB), neuropeptide K (NPK»
Tachykinins represent a family of biologically active peptides wth 10 to 11 amino acid residues, similar sequence of amino acids in the C-terminal region and similar biological effects. In the periphery, tachykinins are mainly localized in C-fibre afferent neurons frequently together with other regulatory peptides such as calcitonin gene-related peptide and galanin. Tachykinins excert numerous effects locally when released from the primary afferents (70) (71) (72) . Tachykinins are normally present in low concentrations in plasma, mainly due to release from the intestine (97) .
Cardiovascular effects
Tachykinins are widely distributed in nervous pathways known to be involved in control of the cardiovascular system. Intravenous infusion of tachykinins including substance P (SP), neurokinin A (NKA), neurokinin B (NKB) and neuropeptide K (NPK) results in dose-dependant decreases in systemic arterial blood pressure due to peripheral vasodilation. The tachykinins have similar potencies in this respect for each of the peptides (98) . Upon intravenous infusion in humans, the vasodilator effects are clearly manifested by bright red flush in the face, a fall in blood pressure and tachycardia (99) . Furthermore, intravenous infusion of tachykinins result in dose-dependant plasma protein leakage in several tissues with similar distribution patterns (98) . The cardiovascular effects of tachykinins are not blocked by antihistamines, atropine or ganglionic blocking agents. Tachykinins have only minor cardiotrophic effects; somewhat increased cardiac output and stroke volume.
Renal effects
Tachykinins are very potent natriuretic substances. They increase renal blood flow, sodium and potassium excretion, and decrease urine osmolality (100, 101) . It is, however, not known whether the plasma concentrations of SP found under physiological conditions participate in the normal salt and water balance of the body. The kidneys play an important role in the metabolism tachykinins which are hydrolyzed by endopeptidase-24.11 present in microvillar membranes derived from the brush border of the renal proximal tubule (102) .
Endothelin
Endothelin is a potent 21 amino acid vasoconstric-154 tor/pressor peptide which is synthesized in and released from vascular endothelial cells. As a matter of fact, three distinct isopeptides of the endothelin family are coded for by three separate genes (103) . It is now established that the vascular/endothelial unit acts as modulator of vascular smooth muscle tone. In addition to vasoconstrictor/pressor actions, endothelin has several biological effects including; a) regional vasodilatory effects, b) positive chronotrophic effects on the heart, c) stimulation of ANP release, d) modulation of noradrenaline release, e) release of eicosanoids or endothelin-derived relaxing factors from the vasculature, f) contraction of intestinal and airway smooth muscle, g) stimulation of proliferation of vascular smooth muscle and fibroblasts. There are receptors for endothelin in the glomeruli and renal papillae which suggest that endothelin may have direct renal actions (104) . Concentrations of endothelin in plasma are below the detection limit of most assays in healthy subjects but clearly detectable in uraemic patients. Plasma endothelin concentrations in patients with uraemia who are not undergoing hemodialysis are lower than in those on maintenance dialysis (105) . Furthermore, it has been established that plasma concentrations of endothelin in the range observed in uraemic patients may contribute to the vascular effects of uraemia (106) .
Neuropeptide Y
NPY has 36 amino acid residues, and is a member of the pancreatic polypeptide family of peptides. NPY coexists with catecholamines in neurons and has been shown to occur mainly in large dense-cored vesicles, whereas noradrenaline is stored both in the large and small vesicles. In the periphery NPY is widely distributed in adrenergic nerves innervating vascular and nonvascular smooth muscle. Arteries are generally more densely innervated than the corresponding veins. NPY is a powerful vasocostrictor with more prolonged effect than noradrenaline (107) .
Cardiovascular effects
Released together with noradrenaline, NPY contributes to the vasocontrictive effects of high-frequency sympathetic nerve stimulation causing the slowly developing and long lasting vasoconstrictor component of the response. Neuropeptide Y affects the sympathetic affector junction at least in three different ways; a) by direct effect (e.g. vasoconstriction) on post-junctional NPY receptors which are not related to adrenoceptors, b) potentiation of the noradrenalineevoked response (e.g. vasoconstriction) and c) by prejunctional suppression of the noradrenaline release. Interacting with noradrenaline, NPY may improve the overall 'cost-effectiveness' of the sympathetic effector junction by reducing the noradrenaline demand and shortening the release of noradrenaline (108) (109) (110) (111) . NPY is probably a major modulator of the autonomous innervation of organs responsible for blood pressure control.
Renal effects
NPY produces marked diuresis and natriuresis with renal vasoconstriction (112, 113) . Infusion of NPY to rats increases the plasma concentration of ANP in rats, indicating that an increase in ANP release may be responsible for NPY-induced natriuresis (114) . Plasma concentrations of NPY and of a large molecular form of NPY is increased in patients with renal failure, and there is a correlation between the plasma concentration of immunoreactive NPY and serum concentration of creatinine (115) . Thus NPY may play a role in the vascular symptoms accompanying chronic renal failure, particularly the hypertensive symptoms.
Vasoactive intestinal peptide (VIP)
VIP has 28 amino acid residues, and shares structural similarities with several other regulatory peptides including secretin and glucagon. In the periphery, nerves containing VIP are most dense in vascular (mainly arterial) structures, nonvascular smooth muscle and glandular structures, but it is also found within the heart and its conducting system. VIP coexists with acetylcholine in central and peripheral parasympatic neurons.
Cardiovascular and renal effects
A potent vasodilator of systemic and pulmonary vessels, VIP also increases cardiac output and myocardial contractility (116) . Furthermore, VIP elevates plasma concentrations of renin. VIP has a direct effect on renal blood vessels and renal tubules to increase the vascular resistence and the fractional sodium excretion (15, 117, 118) . It is possible that VIP, which is released in response to intraduodenal sodium loads (14) , participates in the renal regulation of sodium and water balance.
Diagnosing symptomatic peptide elevations in renal failure
The description of radioimmunoassay (RIA) by Berson and Yalow together with the extraction and separation techniques of R.A. Gregory, V. Mutt and others in the early 1960's opened new possibilities for research on regulatory peptides. The first RIA for a regulatory peptide was reported in 1967 by McGuigan (119) who published the first RIA for gastrin. RIA offers several advantages over traditional bioassay; a) it is at least 2 or 3 orders of magnitude more sensitive than bioassay, being able to detect fmol amounts of the peptide, b) it is fast, simple and cheap, which means that it is praticable in patient care, c) it is very specific for a 3-6 amino-acid portion of the three-dimensional structure of the peptide. This high specificity for few amino acids is, however, also a disadvantage of the RIA compared to bioassay since this particular composition of amino acids may occur in precursor forms of the peptide, the peptide itself or metabolites thereof as well as in other related molecules, which may not at all have the same or similar biological activities as the peptide of interest. Furthermore, the binding of the antibody to the ligands may be influenced by a number of non-specific factors (e.g. high ionic strength, pH changes, high concentration of large proteins), which may contribute to the generally high (8%-15%) intraand inter-assay variabilities, and in some instances falsely indicate the presence of the peptide of interest.
Most RIA methods for regulatory peptides in use today employ polyclonal antisera and labelled antigen in a "competitive" immunoassay system where the unlabelled ligands in the standards or unknown samples compete with the labelled ligand for binding to the antibodies. More recent developments in immunoassay techniques have not as yet improved the assay of regulatory peptides to any major extent. Sandwich-assay systems, where antibodies bind to two different antigenic determinants on the peptide, could provide the badly needed increased specificity to the assays. However, it is unlikely that two macromolecular immunoglobulins at the same time can bind a peptide of 10 to 40 amino-acids with high avidity. The potentially much more specific sandwichassay systems have, therefore, not replaced the traditional competitive assay systems.
Monoclonal antibodies have the advantages of purity, invariance and mass production over polyvalent antibodies. However, monoclonal antisera for regulatory peptides available today are usually of lower avidity than the polyvalent antisera, which results in less sensitive assay systems. It is, however, likely that improved procedures for selecting the antibody producing clones will improve the quality (avidity) of monoclonal antibodies for analysis of regulatory peptides. This is a long-awaited development which may result in mass-produced reagents capable of producing comparable results in many different laboratories. However, even the RIA techniques of today may give valuable clinical information, particularly in patients with endocrine peptide-producing tumours and patients with renal failure, especially if combined with sample extraction and chromatographic methods.
When studying the physiological role of a regulatory peptide, the antiserum used to measure the peptide concentration should preferably not crossreact with precursor forms, metabolites or other related peptides. However, when an antiserum is used to monitor peptide concentrations in chronic renal failure, it should preferably crossreact with as many molecular forms of the peptide family in question as possible since several different molecular forms may be elevated, and the spectrum of molecules is possibly also different in individual patients.
Treatment of symptoms caused by elevations of plasma concentrations of regulatory peptides
It is well established that hemodialysis decreases the plasma concentration of most regulatory peptides which are elevated in chronic renal failure. The reason for this may be either that hemodialysis removes factors that triggered increased release of the peptide or that hemodialysis itself removes regulatory peptides from the circulation. However, in the early stages of chronic renal failure when hemodialysis is not indicated, or when hemodialysis does not sufficiently decrease the plasma concentrations of 156 regulatory peptides, it may be indicated to use synthetic somatostatin analogues which decrease the production and plasma concentration of most regulatory peptides. At present the most well known member of the somatostatin agonist family of drugs is octrecotide.
Octrecotide (SMS 201-995 (Sandoz))
Octrecotide is the first in a row of stable synthetic somatostatin analogues. Octrecotide is a cyclic structure of 8 amino acids with a plasma half-life of 90 min in healthy humans (120) . The prolonged duration of action is due to its resistence to enzymatic deqradation and to its high affinity to somatostatin receptors. Recently it has become apparent that oral administration is likely to become possible (121, 122) . The main effect of octrecotide is to suppress the release of regulatory peptides in general (123, 124) . However, it is possible that it in some instances acts by effects on the peptide effect sites since its effects are almost instantaneous e.g. when used to ameliorate carcinoid crisis. Octrecotide is used in the treatment of acromegaly, endocrine gastrointestinal tumors (125) and some reports have reported beneficial effects in some non-neoplastic diseases of the gut such as the dumping syndrome, esophageal variceal bleedings, peptid ulcer hemorrhage, gastrointestinal fistulas and nonendocrine diarrhoeas (126, 127) . Since chronic renal failure results in elevated plasma concentrations of numerous neuropeptides which are possible contributors to several of the symptoms accompanying the condition, it is surprising that no reports have as yet appeared on the use of octrecotide in controlling symptoms of high levels of regulatory peptides secondary to renal failure.
Doses of octrecotide
In patients with hormone-producing gastrointestinal tumors initial doses of 100 /1g subcutaneously every 12 hours have been used. The doses are subsequently increased to control symptoms to up to a total dose of 1 mg/24 h.
Side effects of octrecotide
Only minor side effects have been reported in patients with endocrine tumors treated with high doses of octrecotide (124, 126, 127) . These include; a) a dose-dependant steatorrhea with doses greater than 550 Jig/day which in some cases responds to pancreatic enzyme supplements, b) burning sensation at the side of injection improved with slow injection of the drug, c) abdominal cramps on initiation of therapy, resolving with continued therapy, d) abnormal glucose tolerance due to suppression of glucose release, however, neither glycosuria or frank diabetes has been reported, e) accumulation of thickened bile, gallstones and biliary cholic may be caused by octrecotide and gives reasons for ultrasound examination of all patients before the initiation of therapy and f) light-headedness and/or nausea immediately after and for a few minutes after the injection that gradually fades with repeated injections.
Plasma concentrations of endogenous somatostatin in renal failure
There is a controversy with regard to the plasma levels of somatostatin in renal failure. Lundquist et al. found the plasma concentrations of somatostatin in uremic patients is considerably higher than in healthy subjects. About 75% of the immunoreactivity consists of somatostatin 28 whereas about 25% represented somatostati n 14 (129) . It is, however, unknown whether endogenous somatostatin participates in the control of concentrations of other regulatory peptides in chronic renal failure.
